Kezar Life Sciences Inc

NASDAQ:KZR   10:12:16 AM EDT
14.72
+0.06 (+0.41%)
Regulatory, Earnings Announcements

Kezar Life Sciences Announces Interim Results From Mission Phase 2 Trial In Patients With Lupus Nephritis

Published: 11/15/2021 21:32 GMT
Kezar Life Sciences Inc (KZR) - Kezar Life Sciences Announces Interim Results From Mission Phase 2 Trial in Patients With Lupus Nephritis.
Kezar Life Sciences Inc - Kzr-616 Maintained a Favorable Safety and Tolerability Profile Over Six-month Treatment Period.
Kezar Life Sciences Inc - Top-line Data From Phase 2 Mission Trial in Patients With Lupus Nephritis Are Expected in Q2 of 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.30

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.32

More details on our Analysts Page.